### Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

	Euga			EUTICST			
CORCEPT THERA Form 4 April 18, 2007	APEUTICS IN	С				0.15	
FORM 4	UNITED STA	TES SECUR	ITIES AND EXC	HANGE	COMMISSION		APPROVAL
Check this box Check this box							ours per
(Print or Type Response	es)						
BELANOFF JOSEPH K Symbol			Name <b>and</b> Ticker or T PT THERAPEUT	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
			te of Earliest TransactionX_ Director hth/Day/Year)X_ Officer (give below) 6/2007 Chief E			X 10% Owner e title Other (specify below) Executive Officer	
			ıdment, Date Original h/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting Person</li> </ul>			
(City) (Sta		Table	I - Non-Derivative S	ecurities Ac	Person	of, or Benefici	ally Owned
	an	A. Deemed ecution Date, if	3. 4. Securit TransactionAcquired Code Disposed (Instr. 8) (Instr. 3, 4 Code V Amount	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock					300,000	I	Custodian for a minor daughter <u>(1)</u>
Common Stock					300,000	I	Custodian for minor son <u>(1)</u>
Common Stock					2,164,195	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative 6. Date Exercisable Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Stock option (right to buy)	\$ 1.5	04/16/2007		А	1,000,000		(2)	04/16/2017	Common Stock	1,000,0

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
BELANOFF JOSEPH K C/O CORCEPT THERAPEUTICS 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025	Х	Х	Chief Executive Officer			

# Signatures

s/s Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated 04/18/2007 attorney-in-fact Date

\*\*Signature of Reporting Person

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person is the custodian for minor children and disclaims beneficial ownership of the shares, except to the extent of his (1)pecuniary interest therein.
- Exercisable with respect to 2.0834% of the total number of Option Shares on the monthly anniversary of 4/16/2007 each month (2) thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.